Brain Tumor Combination Therapy Sequencing for Radiation Sensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for brain tumors, particularly those driven by mutant IDH1 or IDH2 enzymes, face challenges such as desensitization to radiation therapy and limited efficacy of single-agent inhibitors, leading to unfavorable clinical outcomes and tumor progression.
Innovation Solution
A combination therapy involving a compound of formula (I) or its pharmaceutically acceptable salt, alongside radiation therapy and/or additional therapeutic agents like DNA-reactive agents, PARP inhibitors, anti-emesis agents, anti-convulsants, checkpoint inhibitors, PVC chemotherapy, bevacizumab, or gemcitabine, is administered to treat brain tumors, allowing for synergistic effects in reducing tumor size, inhibiting growth, and improving survival rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If mutant IDH1 inhibitors are administered during radiation therapy, then tumor growth is repressed, but radiation sensitivity decreases leading to unfavorable clinical outcome
Solution Approach 1:
The treatment regimen is segmented into distinct phases: radiation therapy is administered first, followed by mutant IDH1 inhibitor treatment after the radiation course is completed. This temporal segmentation prevents the inhibitors from interfering with radiation sensitivity during the critical treatment period, while still providing tumor growth repression in the subsequent phase.
Solution Approach 2:
Radiation therapy is performed as a preliminary action before initiating mutant IDH1 inhibitor treatment. This ensures that the tumor receives full radiation effect without pharmacological interference, and the inhibitors are only introduced after the radiation sensitivity window has passed.
2Productivity
If single-agent mutant IDH1 inhibitors are used, then tumor growth is inhibited, but desensitization to radiation therapy occurs and efficacy is limited
Solution Approach 1:
The therapeutic approach segments the treatment into two distinct components administered at different times: radiation therapy as the first component, and mutant IDH1 inhibitor as the second component. This avoids the development of resistance or desensitization that occurs when the inhibitor is present during radiation exposure.
Solution Approach 2:
The patent combines radiation therapy and mutant IDH1 inhibitor treatment into a comprehensive therapeutic regimen, but sequences them temporally rather than administering concurrently. This merging allows both modalities to contribute to tumor control while avoiding their adverse interaction.
3Reliability
If mutant IDH1 inhibitors are administered concurrently with radiation therapy, then enzyme activity is blocked, but therapeutic benefit is reduced due to desensitization
Solution Approach 1:
Radiation therapy is performed as a preliminary action to establish initial tumor control, followed by the introduction of mutant IDH1 inhibitors after the radiation course. This sequencing ensures maximum therapeutic benefit from radiation while still achieving enzyme inhibition for ongoing tumor suppression.
Solution Approach 2:
The treatment employs periodic action by administering radiation therapy in a defined course, then transitioning to a maintenance phase with mutant IDH1 inhibitors. This periodic approach optimizes the therapeutic window for each modality while maintaining continuous disease control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy enhances therapeutic benefits by increasing complete response, partial response, stable disease, overall survival, and progression-free survival in patients with glioma, compared to monotherapy, by effectively targeting mutant IDH enzymes and enhancing radiation sensitivity.
Implementation Method 1
mutations of IDH1 present in certain cancer cells result in a new ability of the enzyme to catalyze the NAPH-dependent reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG)
Implementation Method 2
administering to the patient (a) a compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) radiation therapy
Data Source
Figure 1
Figure 2
AI summary
Provided are methods of treating a brain tumor in a patient in need thereof comprising administering to the patient a compound described herein and radiation therapy and/or one or more additional therapeutic agents.